Author

Maria Lorenzo

Departamento de Biotecnologia, INIA CSIC, Carretera La Coruna km 7.5, E-28040 Madrid, Spain.;

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Adrien Le Thomas· 1 shared Aitor NogalesiD· 1 shared Alvin Gogineni· 1 shared Amy Heidersbach· 1 shared Avi AshkenaziiD· 1 shared Benjamin Haley· 1 shared Daniel W Sherbenou· 1 shared David A Lawrence· 1 shared

Activity by Year

2018-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrien Le Thomas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintNov 13, 2026

A bivalent VP2 based vaccine approach reveals co expression driven interference between VP2 antigens impairing BTV neutralizing antibody induction

Luis Jimenez-Cabello, Juana Sanchez-Puig, Ivan Mazuecos-Aragones…·Javier Ortego

This study develops a bivalent vaccine approach using BTV VP2 antigens and finds that co-expression of VP2 proteins interferes with neutralizing antibody induction, while monovalent vaccines provide effective protection.

DOI 10.64898/2026.11.11.764333

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 14, 2018

Disruption of IRE1α through its Kinase Domain Attenuates Multiple Myeloma

Jonathan M Harnoss, Adrien Le Thomas, Scot A Marsters…·Avi Ashkenazi

This study shows that disrupting IRE1α's kinase domain reduces multiple myeloma tumor growth and enhances treatment efficacy, suggesting it as a therapeutic target.

DOI 10.1101/495242

humanbulk RNA-seq

𝕏 PostBluesky